OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

REGISTERED COMPANY NUMBER.. 02361986 (England and Wales) REGISTERED CHARITY NUMBER: 801279 THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIM￿ED la company limited by guarantee) REPORT OF THE TRUSTEES AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 Wenn Townsend Chartered Accountants Oxford

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED REFERENCE AND ADMINISTRATIVE DETAILS Registered company number.. 02361986 (England and Wales) Registered charity number.. 801279 Trustges: Miss M Ainsworth-wells MrESDale Mr N H Riley (resigned 3 March 20251 Dr C B Shepherd Mr D A Allen Mr M Mitchell Registered office: Unit 7 Apollo Office Court Radclive Road Gawcott Buckingham Buckinghamshire MK184DF Auditors: Wenn Townsend 30 Sl Giles Oxford OX13LE

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 Page Report of the Trustees 1to9 Report of the Independent Auditors 101012 Statement of Financial Activities 13 Balance Sheet 14 Statement of Cash Flows 15 Notes lo the Statement of Cash Flows 16 Notes lo the Accounts 171028 Detailed Statement of Financial Actwities 29

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025 The Iruslees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the audited financial slalemenls of the charity for the year ended 31 December 2025. The trustees have adopted the provisions of the Statement of Recommended Practice ISORPI "Accounting and Reporting by Charities in preparing the annual report and the financial statements of the Charity. OBJECTIVES AND ACTIVITIES Charitable Objectives The charity's vision is to improve the quality of life for those affected by MEICFS. We do this by providing support and information", funding research lo find biomedical markers and treatments and educating and informing the broad eco-system that includes media, politicians, educators, health and social care providers and the commercial sector. What we do and why we do It The ME Association is one of the leading national charities for people with MEICFS (Myalgic Encephalomyelitis or Encephalopathy., Chronic Fatigue Syndrome) and it is also the longest running UK charity, having been founded in 1980. In the last 45 years, we have established an excellent reputation and consistently deliver high standards of support, reliable and timely information, effective lobbying, influencing, and we continue lo raise awareness of MEICFS within the public and lo help further educate health care and social care professionals. Over the years, the ME Association has funded a range of medical research studies in the hope they may find a biomarker or an effective treatment for the disease. As there are important clinical and pathological overlaps be￿een MEICFS and Long Covid, we also provide information for people who have this condition post the Covid19 pandemic. MEICFS is mulli-systemic disease and around 400,000 people in the UK have this debilitating illness with an estimated 1.8m having Long Covid. Symptoms include profound fatigue, sleep disturbance, post-exertional malaise, cognitive difficulties and a range of other symptoms like pain, headaches, nausea and intolerance lo lights and noise. These are life-changing and indiscriminate medical conditions that affect both adults and children regardless of socio-economic or ethnic background. MEICFS is a doubly invisible illness." not only are symptoms hard to see but the disease attraels little understanding from the public or the Medical profession. This leads lo people with MEICFS experiencing prejudice and disbelief, making them feel stigmatised and isolated. MEICFS can lead to long-lerm disability and a lower quality of life than Multiple Sclerosis or Cancer. It most often presents as a complex post-infeclion syndrome that dramatically impacts a person's ability to complete everyday tasks and to mobilise normally. Long Covid affects people in a similar way. There are no effective drug Irealments, but convalescence and appropriate self-managemenl can help stsbilise and improve functional ability over lime for some people. Complete recovery from MEICFS is rare and for people who are severely affected the disease can be life-changing and in some cases life-threalening. Support & Information We provide support and information for.. People with a diagnosis of MEICFS & Long Covid.. SLJb- groups." 25 % severe and very severe ME,. 75'/o moderates to mild., People with symptoms bul no diagnosis., Carers, Family members, Friends. Information covers". Daily life with MEICFS & Long Covid", Understanding MEICFS & Long Covid", Early and Accurate Diagnosis", Managing MEICFS & Long Covid, Provision of and access to information on good management and social care INICEI,. Awareness and Recognition (Remove Stigmal,. Benefits awareness and accessibility,. Employment and Education,. Outcomes of research that may be relevant to the management of those with MEICFS. Progress with research - what's coming up,. How to care for someone with MEICFS.

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025 OBJECTIVES AND ACTIVITIES Icontinuedl We identify the most relevant information and appropriate channels, platforms, partners and people in order lo reach people with MEICFS and those with symptoms but no diagnosis.. those who care for them and support them., intermediaries from whom they may seek support and information. These include". A safe and welcoming Membership community for people affected by these conditions who come together and benefit from sharing their experiences. A comprehensive website, and large range of free downloadable literature, covering all aspects of life with MEICFS and Long Covid. The ME Connect telephone information and support service and by responding effectively to a g￿al many email and social media ￿qUeStS for help. A membership magazine IME Essenliall, newsletter and our website and social media platforms. Educatlng & Influenclng Our audience includes.. Healthcare Professionals I Social Care Professionals., Medical Professional organisalions. e.g. The Medical Royal Colleges., The NHS (Primary & Secondary Carel., Parliament., Media (Publicl . All UK Govts., Healthcare commissioners. Information provision includes.. Diagnosis of MEICFS, the Importan￿ of having an Early and Accurate Diagnosis,. The 2021 NICE Guideline Recommendations,. How lo improve and create good specialist services., How to develop effective clinical pathways,. How to generate good care and support plans,. How lo provide ongoing care and support In primary & secondary care, and social care servicesl DHSC prioritising MEICFS., Awareness and Recognition (Remove Sligmal", Benefits awareness and accessibility l Employment and Education., Outcomes of research that may be relevant to the management of those with MEICFS. Progress with research We identify the most appropriate channels, platforms, partners and people lo reach health & social care,. political,. media., employment, insurance & pension professionals and bodies in and outside the field of MEICFS. These include.. A dedicated Health and Social Care team who both respond to and actively approach the health and social care sector Medical Matters- a medical magazine for health professionals A dedicated Press Officer who responds to media enquiries and drives media through the placement of stories across appropriate media platforms Collaboration and support for Forward-ME, the ME Research Collaborative, DecodeME, The All-Party Parliamentary Group on ME, Chronic Illness Inclusion, and UK Long Covid initiatives. Campaigns targeted lo raise awareness and bring about positive change within medical sellings such as GP surgeries and as campaign partners for the national 'Carers' Week,

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025 Research Our primary audience includes. Research professionals IMEICFS & Long covidl., Research professionals Inon-MEICFS & Long ¢ovidl and Secondary las a route lo the above).. ME Research Collaborative,. MRC., NIHR., Pharmaceutical Companies ,' Other research funding charities. Information includes". The role of the MEA & access lo our research funds including Ramsay Research Fund," MEICFS & Long Covid," Vlthy research is critical." Understanding causellriggers, Understanding perpelualion," Developing effective treatments," What biomedical research has been done already and what is missing. We identify the most appropriate channels, platforms, partners and people lo reach research professionals in and outside the field of MEICFS and issue grants and contracts lo relevant projects. These include.. The MEA Ramsa Research Fund funds biomedical research into cause and management of MEICFS. This includes all the basic running costs for the MEICFS Biobank at the Ro al Free Hos ital in London which collects blood samples and anonymised clinical data from people with MEICFS, Multiple Sclerosis IMS) and healthy controls. The ME Association also works with the Manchester Brain Bank on post-mortem research. This arrangement means that we will be able lo obtain pathological information about specific parts of the brain, spinal cord and dorsal root 9anglia where symptoms, abnormalities and neuroimaging studies have already indicated they could be involved in causing or perpetuating the disease. The ME Association is funding or considering funding almost every research group in the UK that is carrying out biomedical research into the cause or management of MEICFS - a total of 12 different centres or individuals. This includes, in December 2025, Imperial College London being awarded £1.1 million by The ME Association to lead the Rosetta Stone study, the largest research project of ils kind which will enable lop scientists in their field to conduct side-by-side cellular and molecular analyses of MEICFS and Long Covid offering an Unpre￿dented look into what these conditions share and taking us closer to diagnostic biomarkers and treatment pathways. Public benefit In preparing these financial statements and their report, the Trustees confirm that they have had regard to the Charity Commission's guidance on public benefit. and that they consider the objectives and activities of the charity have historically and continue to fall within the scope of that guidance. Fundraising standards information As part of the overall 5-year fundraising strategy the approach for 2025 was to continue and strengthen a range of fundraising methods so that the charity was not dependent on one type. This included increasing the challenge event portfolio, introducing new community fundraising products, developing major donor relations and creating a trusts programme. The charity is a member of the Fundfftising Regulator and conducts all fundraising activities using the Codes of Practice and Fundraising Promise. Additionally, all fundraising staff currently hold qualifications through the Chartered Institute of Fundraising. There have been no instances of failure lo comply with the fundraising codes of practice or the fundraising promise. All charity fundraisers are asked to register their detsils with the charity. Regular communication follows ensure both legal and best practice is adhered to within any fundraising activities. There were no complaints received by the charity from fundraising activities in 2025. The charity's fundraising activities operate within the published privacy policy. All activities are carried out using the Fundraising Regulators guidelines on consent and data protection, see section 5.2 Safeguarding and working with people in vulngrable Gircumslances. The charity does not employ external fundraising agencies to solicit donations from members of the public. All volunteer fundraisers are advised to adhere to the Fundraising Regulators, guidelines.

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025 ACHIEVEMENTS AND PERFORMANCE 2025 was another significant year for the MEA. A year marked by meaningful progress, ongoing challenges, and renewed determination in our mission lo Improve the lives of people with Myalgic Encephalomyelitis IMEI, including those living with post-infectious conditions and Long COVID that overlap with MEICFS. Support Supporting our community remains the heart of our work. Demand for our services continued to grow, particularly among individuals with severe or very severe ME and those newly affected following viralllriggering illnesses. Our support line, information services, and online resources remain a lifeline for thousands, offering trusted guidance, emotional support, and praclieal help al every stage of illness. This year, we also launched new educational materials focusing on pacing, symptom management, and navigating disability and workplace rights, along with the launch of a dedicated panel for those severely affected. Educate and Influence Throughout the year, the ME Association has continued to sland fimily with people whose voices are often unheard. We intensified efforts lo ensure that policymakers, healthcare leaders, and research institutions understand the urgent need for better services, compassionate care pathways, and increased biomedical funding. Our submissions lo government consultations, participation in advisory groups, and public-facing campaigns have helped place MEICFS firmly on the national health agenda. Although systemic change remains gradual, our Influen￿ continues to build. Raising awareness and public understanding is essential to improving quality of life for people with MEICFS. In 2024-25, we expanded our digital outreach, engaged new audiences through community events and public campaigns, and strengthened partnerships with employers and healthcare organisalions. ME Awareness Month featured our mostvisible campaign yet, amplifying patient stories and highlighting the profound impact of this illness and our participation in Carers, week 2025 pul those who support people with MEICFS in the heart of Parliament. In September, we hosted our Lives We Cannot Live exhibition at London's Oxo Gallery, in partnership with filmmaker and photographer Jeremy Jeffs. It generating over £150,000 in free publicity, reaching new audiences. We are working with the DHSC and NHS England on progressing several important actions from the DHSC Delivery Plan on MEICFS. These include helping lo prepare a template service specification for the specialist MEICFS referral clinics, setting up a national referral service for people with very severe MEICFS who require hospitsl admission, and working with the Royal College of Physicians on various medical education initiatives. Research 202￿25 saw significant strides in biomedical resea￿h, supported by the continued generosity of our members and donors. We expanded grants to studies exploring immune dysfunction, post-infectious triggers, autonomic impairment, and potential biomarkers, while pursuing collaborations with clinicians and scientists nationally and inlernationalty. These efforts contribute to a growing global network etermined lo unravel the complex biology of ME. We are committing nearly £2 million to research over the next three years, including £1.1 million for the Rosetta Stone study, the largest single investment in biomedical research ever made by a UK charity in this field. This groundbreaking work aims to help wodd-leading scientists uncover shared pathways between MEICFS and Long COVID.

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025 ACHIEVEMENTS AND PERFORMANCE {continuedl Operational Resilience and Governance Behind the s￿nes, the Association has continued to prioritise governance. financial sustainability, and operational efficiency. Following discussions at the December 2024 AGM, we commissioned an independent governance review of the charity. The review produced 49 recommendations, ranging from minor procedural updates to substantial long-term structural changes. The new organisational structure and enhanced stmtegic focus reflects a large proportion of the recommendations, with the remaining being targeted for completion in 2026-7. The charity's financial position remains positive. However, with increasing demands from additional stsffing and the awarding of significant research grants, we are operating sustainably on our current reserves and have restructured our management framework lo focus on financial management and income generation via the creation of two new Director roles. A continual review of the organisational structure, including roles such as Chief Executive OffI￿r or Chief Operating Officer, will be undertaken when financially and strategically viable. Over the next 12 months however, our campaigns will place a strong emphasis on income generation lo support our work and secure long-lerm sustainability. We have also invested in new digital infrastructure, improved reporting and transparency, and strengthened volunteer engagement. These initiatives enable us to better serve our members and position the organisation for long-lerm stability and growth. Looking Ahead The coming year presents both challenges and opportunities. Our priorities for 2026 include.. Pushing for equitable healthcare, Accelerating biomedical research, Maintaining support services, and Ensuring that every person with MEICFS feels seen, believed, and valued. th our major commitment to research, the next 12 months will emphasise consolidation, allowing income streams to stabilise and providing space for necessary restructuring.

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025 Financial review In 2025, The ME Association saw total funds decrease by £341,053 bringing the year end balance to £3.520, 817. Income Total income for the year was down by £223.715 compared lo 2024, which is a result of significantly lower legacy income but is offset by higher donations and fundraising income. Membership subscription income remained consistent with 2025 levels. Vvhile this represents a relatively modest portion of our overall revenue, membership contributions continue playing a meaningful role in supporting the day-104ay operations of the charity. We saw a decrease in legacy income in 2025. The total for legacy income re￿iVed in the year was £296,533 compared with £628,031 in 2024. Legacies remain a vital and appreciated source of funding for our work. We are deeply grateful to all supporters who remember the ME Association in their wills. Unless any donation, legacy or fundraising income is expressly reslricled lo the purpose of funding research activities, all income is allocated to the charity's general funds. These general funds can be applied towards research activities alongside restricted funds when appropriate. Expenditure Total expenditure increased by £370.398 compared with the previous year. In 2025 we spent an additional £142k on research compared with 2024. A fvll breakdown of reSea￿h expenditure can be foLJnd in the notes lo the accounts. We continued to expand our teams across Fundraising, ME Connect, the Health & Social care team and engaged with a PR consultant which reSu￿ed in higher stsff and contractor costs in the year. The Audit, Investment and Risk Committee met regularly throughout the year to oversee financial management, improve govemance and internal controls, manage organisational risk and lo assess research funding applications presented by the Research Committee. Their work supports the Board in fulfilling its duties and supporting long-lerm planning for the future of the charity. Reserves Totsl Funds Held Al 31 December 2025, the ME Association held total funds of £3.520.817 Investment Approach The ME Association carefully considers all potential investments and recognises its responsibility as steward of the funds received from our generous supporters and donors. The charity will always try to act in the best interests of its beneficiaries and supporters. The Trustees review reserves regularly to ensure funds are managed effectively, balancing financial security with the need lo support the charity's objectives. The Trustees aim to maintain reserves equivalent lo a minimum of 12 months of unrestricted operating costs estimated at £945,000. This calculation includes unreslricled costs but excludes reslricled research expenditure and depreciation. This would enable the charity to continue meeting its operational and membership obligations, in the event of unforeseen circumstances or a reduction in income.

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025 Financial review continued Unrestricted funds Unreslricled funds al year-end tolalled £2,904,690 12024.. £3,086,948), representing a decrease of £182,258 during the year. These funds provide flexibility lo respond to emerging needs, invest in future development, and supplement reslricled funds when appropriate. Restrlcted funds The ME Association holds restricted funds solely for the purpose of financing biomedical research into the causes, diagnosis and treatment of MEICFS. These are principally held in the Ramsay Research Fund and must be used in line with donor intent. As of 31 December 2025, restricted reserves stood at £616.127 12024.. £774,922), representing a decrease of £158,795 during the year. The charity recognises its obligation lo relain sufficient restricted reseNes lo meet both existing and future research commitments. In the event of the charity being wound up, any remaining restricted funds would be transferred lo a UK charity with objectives closely aligned with supporting and publishing MEICFS research. Freg Reserrfes Free reserves, which are defined as unrestricted funds, excluding designated reserves and the net book value of fixed assets, stood at £1.558.840 at 31 De￿mber 202512024.. £1,220,357). The increase in free reserves is a result of removing core services from designated funding. Designated Reserves Within unrestricted funds, the ME Association has designated £1,250,000 to support specific strategic and operational priorities.. £15,000- designated as a slnklng fund lo cover potential future repairs lo the charity's office premises. £235.000 designated to the general healthcare research fund for approved future expenditure relating to the diagnosis, management, and treatment of MEICFS and Long Covid. £1,000,000- designated for approved Research Projects. These funds have been set aside from general reserves. Once restricted funds have been fully expended an appropriate sum will be transferred from general reserves to restricted funds. STRUCTURE, GOVERNANCE AND MANAGEMENT Governing document The charity is established under a Memorandum of Association which established the objects and powers of the charitable company and is governed by Ils Articles of Association. Charity constitution The charity constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025 embership Members subscribe annually and voting rights are based on the currency of their subscription. Members ofthe charitable company guarantee to contribute an amount not exceeding £1 to the assets of the charitable company in the event of winding up. Recrultment and appolntment of new trustees The charity is managed by elected trustees. The Articles of Association require that one third of the trustees retire every two years bul remain eligible for re-election. Trustees are elected by the members of the charity and must comprise of people with an interest in MEICFS. Applications to become a trustee are advertised in both the quarterly magazine of the charity and its social ne￿Ork media. We welcome applications from individuals who bring real-life experience, professional skills, a willingness lo work collaboratively, and above all share our passion for improving the lives of those living with MEICFS. There is a limit of eight Iruslees, bul the Board can co-opt up to three additional members al any time. Co-opted trustees are then pul forward lo the membership for election al the next annual general meeting IAGMI al which elections will lake place. Voting takes pla￿ by either postal ballot or at the AGM. Risk Managemont The Trustees have conducted their own review of the major risks lo which the charity is exposed, and systems and policies have been established to miligale those risks. Organisational structure and how the charity makes decisions Following a consultation al the end of 2025 the ME Association introduced a revised operating structLJre in March 2026. Under this structured department heads and directors will work together to develop budgets and strategic business plans. The proposals will be presented lo the board of trustees for consideration and approval. The trustees are ￿sponSible for the overall governance stmtegic direction of the charity. Policies and procedures for induction and training of trustees The charity is committed lo ensuring that new Iruslees are appropriately inducted, supported and trained lo fulfil their responsibilities effectively. New trustees initially join the Board for a 12-monlh period as Associate Trustees, after which they may be appointed as full Trustees if considered suitable. They re￿1ve an induction programme designed lo familiarise them with the charity's objectives, governance structure, strategic priorities, financial position, legal obligations, and key policies and procedures. Key management personnel remungration The Iruslees are responsible for setting the remuneration of the key management personnel. Pay levels are reviewed annually to ensure they remain fair and reasonable. In setting remuneration the charity considers". Responsibilities and required experien￿ for the role. Remuneration is compared with similar size charities. The financial position of the charity.

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025 STATEMENT OF TRUSTEES. RESPONSIBILITIES The Iruslees Iwho are also the directors of The Myalgic Encephalopathy Association Limited for the purposes of company lawl are responsible for preparing the Report of the Trustees and the financial statements in awordance with applicable law and United Kingdom Accounting Stsndards (United Kingdom Generally Accepted Accounting Pracb"Trl. Company law requires the trustees lo prepare financial statements for each financial year which give a true and fair view of the stale of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to select suitable accounting policies and then apply them consistently", observe the methods and principles in the Charity SORP 2019 IFRS1021", make judgements and estimates that are reasonable and prudent", slate whether applicable accounting standards have been followed., prepare the financial statements on the going concem basis unless il is inappropriate to presume that the charitable company will continue in business. The trustees are responsible for keeping adequate accounting records which disclose with reasonable accuracy al any lime the financial position of the charitable company and lo enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hen￿ for taking reasonable steps for the prevention and detection of fraud and other irregularities. In so far as the Iruslees are aware.. there is no relevant audit infomialion of which the charitable company's auditors are unaware,. and the Iruslees have taken all steps that they ought to have taken lo make themselves aware of any relevant audit information and lo establish that the auditors are aware of that information. AUDITORS The auditors, Wenn Townsend, will be proposed for re-appointment al the forthcoming Annual General Meeting. This report has been prepared having taken advantage of the small companies exemption in the Companies Act 2006. Approved by order of the board of trustees, as the company directors, on 23rd June 2026 and signed on the board's behalf by". Mr D A Allen- Trustee

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED Opinion We have audited the financial statements ofThe Myalgic Encephalopathy Association Limited Ithe'charitable company'l for the year ended 31 December 2025 which comprise the Statement of Financial Activities, the Balan￿ Sheet, the Cash Flow Statement and notes lo the financial slalemenls, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation Is applicable law and United Kingdom Accounting Standards (United Kingdom Generalty A¢￿pIed Accounting PracliTrl, including Financial Reporting Standard 102'The Financial Reporting Standard applicable in the UK and Republic of Ireland,. In our opinion the financial stslemenls.. give a true and fair view of the state of the charitable company s aff8irs as 8t 30 December 2025, and of its incoming resources and appliealion of resources, including its income and expenditure for the year then ended", have been properly p￿pared in accordance with United Kingdom Generally Accepted Accounting Practice", and have been prepared in aecordance with the ￿quirementS of the Companies Act 2006. Basls for oplnlon We conducted our audit in accordan￿ with Intemational Standards on Auditing IUKI IISAS IUKII and applicable law. Our responsibilities under those stsndards are further described in the Auditors, responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant lo our audit of the financial ststemenls in the UK, including the FRC'S Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtsined is sufficient and appropriate to provide a basis for our opinion. Conclusions relating to going concern In auditing the financial stslemenls, we have concluded that the trustees, use of the going concern basis of accounting In the preparation of the financial statements is appropriate. Based on the work we have performed, we have not idenlilied any material uncertainties relating to events or conditions that, individually or collective￿, may cast significant doubl on the charitable company's ability to continue as a going con￿rn for a period of at least ￿e1ve months from when the financial statements are authorised for Issue. Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. Other Infomiatlon The other information comprises the information included in the Annual Report, other than the financial ststements and our Report of the Independent Auditors thereon. The Iruslees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly staled in our report, we do not express any fom of assurance conclusion thereon. Our responsibility is lo read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial ststemenls or our knowledge obtained in the audit or otherwise appears lo be materially misstated. If we identify such material inconsistencies or apparent material misslatemenls, we are required lo detemiine whether this gives rise to a material misslalemenl in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misslatemenl of this other information, we are required to report that fact. We have nothing to report in this regard. Opinions on other matters prescribed by the Companies Act 2006 In our opinion, based on the work undertaken in the course of the audit.. the information given in the Report of the Trustees Iwhich includes the directors, report prepared for the purposes of company lawl for the financial year for which the financial statements are prepared is consistent with the financial statements., and the directors, report has been prepared in accordan￿ with applicable legal requirements. 10

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED Matters on which we are required to report by exception In the light of our knowledge and understanding of the charitsble company and its environment obtained in the course of the audit, we have not identified material misstalemenls in the directors, report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us lo report to you if, in our opinion.. adequate accounting records have not been kept, or relums adequate for our audit have not been received from branches not visited by us., or the financial statements are not in agreement with the accounting records and retums., or certain disclosures of directors, remuneration specified by law are not made,. or we have not received all the information and explanations we require for our audit., or the trustees were not enlilled lo prepare the financial statements in accordance with the small companies, regime and lake advantage of the small companies, exemptions in preparing the directors, report and from the requirement lo prepare a strategic report. Responsibilities of trustees As explained more fully in the Statement of Trustees, Responsibilities, the trustees Iwho are also the directors of the charitable company for the purposes of company lawl are responsible for the preparation of the financial slalemenls and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary lo enable the preparation of financial statements that are free from material misslatemenl, whether due to fraud or error. In preparing the financial statements, the Iruslees are responsible for assessing the charitable company's ability lo continue as a going concern, disclosing, as applicable, mallers related to going concern and using the going ¢on¢ern basis of accounting unless the Iruslees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but lo do so. Auditor's responsibilities for the audit of the financial Statements Our objectives are lo obtain reasonable assurance about whether the financial ststemenls as a whole are free from material misstalemenl, whether due lo fraud or error, and lo issue an auditor's report that Includes our opinion. Reasonable aSSU￿nCe is a high level of assurance, but is not a guarantee that an audit conducted in accordanee with ISAS IUKI will always detect a material misstatement when it exists. Misslatemenls can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial stalemenls. Irregularities, including fraud, are instan￿5 of non-compliance with laws and regulations. We design procedures in line with our responsibilities, oudined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below.. Enquiry of management and those charged with governance around actual and potential liligalion and claims., Enquiry of management and those charged with governance lo identify any instances of non- Complian￿ with laws and regulations., Reviewing minutes of meetings of those charged with governance., Reviewing financial statement disclosures and testing lo supporting documentation to assess compliance with applicable laws and regulations", Performing audit work over the risk of management override of controls, including lesling of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias. Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that Complian￿ with a law or regulation is removed from the events and transactions refiected in the financial statements, as we will be less likely to become aware of instances of non-complian￿. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website al.. www.trc.org.ukJaudilorsresponsibilities. This description forms part of our auditor's report. 11

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED Use of our report This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might stale to the charitable company's members those matters we are required to slate lo them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed. frw Benjamin Hayes Bsc FCA (Senior Statutory Auditor) For and on behalf of Wenn Townsend 30 St Giles Oxford OX1 3LE 23rd June 2026 12

00 I￿ 3 TJ TJ rfi TJ CJ Jcwo J(r

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2025 Note 2025 2024 Cash flows from operating activities Nel cash provided by operating activities 1213,4571 200,043 Cash flows from investing activities Purchase of tangible fixed assets 11,9511 15,7561 Ilncreaselldecrease in term deposits 206,537 1272,3051 Interest received 161,983 98,969 Net cash provided byllused inl investing activities 366,569 1179,0921 Cash flows from flnanclng actlvltles Interest paid 17,0401 18,0971 Net cash used in financing activities 17,0401 18,0971 Change in cash and cash equivalents in the yoar 146,072 12,854 Cash and cash equivalents at the beginning of the year 1,207,938 1,195,084 Cash and cash equivalents at the end of the year 1,354,010 1,207,938 15

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED NOTES TO THE STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2025 RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES 2025 2024 Net incomellexpenditurel for the year las per the Statement of Financial Activities) 1341.0531 253,060 Adjustments for: Depreciation charges Interest re￿iVed Interest pai Iln¢reaselldecrease in stocks Decrease in debtors Increase in creditors 12.692 1161.9831 7.040 {1.5851 248.701 22,731 11,920 198,9691 8,097 690 24,022 1,223 Net cash provided by operations 213 457 200,043 ANALYSIS OF CHANGES IN NET FUNDS Cash flows At 1.1.25 At 31.12.25 Net cash Cash at bank and in hand 1,207,938 146.072 1,354,010 Liquid resources Current asset investments 2.278.750 1206.5371 2.072.213 3,486,688 60.465 3,426,223 16

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 1 ACCOUNTING POLICIES Basis of preparing the financial statements The company is a company limited by guarantee. The members of the company are the Trustees named on page 1. In the event of the company being wound up, the liability in respect of the guarantee is limited to £1 per member ofthe company. The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities.. Slalemenl of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland IFRS 1021, the Charities Act 2011, the Companies Act 2006. and UK Generally AC￿pIed Accounting Practi￿. The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items al fair value. The financial statements are presented in sterling which is the functional Cur￿ncY of the charity and rounded to the nearest £. The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated. Income recognition All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably. For donations to be recognised the charity will have been notified of the amounts and the settlement date in writing. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained then income is deferred until those conditions are fully met or the fulfilmenl of those conditions is within the control of the charity and it is probable that they will be fulfilled. For legacies, entitlement is taken as the eadier of the date on which either., the company is aware that the probate has been granted, the estste has been finalised and notifi'cation has been made by the executorlsl lo the Trust that a distribution will be made, or when a distribution is received from the eslale. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the company has been notified to the executorfs intention lo make a dislribulion. Where legacies have been notified to the company, or the company Is aware of the granting of probate, and the criteria for income recognf(ion have not been met, then the legacy is Irealed as a contingent asset and disclosed if material. Gifts in kind donated for distribution a￿ included al valuation and recognised as income when they are distributed lo the projects. Gifts donated for resale are included as Income when they are sold. Donated facilities are included al the value to the company where this can be quantified and a third party is bearing the cost. No amounts are Included in the financial statements for services donated by volunteers. Donated services of facilities are recognised when the company has control over the item, any conditions associated with the donated item have been mel, the receipt of economic benefit from the use of the company of the item is probable and that economic benefit can be measured reliably. In accordance with Charities SORP IFRS 1021, the general volunteer lime of the Friends is not recognised and refer lo the Trustees, report for more information about their contribution. On receipt, donated professional services and donated facilities are recognised on the basis of the vslue of the gift lo the company which is the amount the company would have been willing to pay to obtain seNices or facilities of equivalent economic benefit on the open market,. a corresponding amount is then recognised in expenditure in the period of receipt. other income is recognised in the period in which il is recoverable and to the exlenl the goods have been provided or on completion of the servi￿. 17

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 1 ACCOUNTING POLICIES {continued} Expenditure recognition Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation commilling the charity lo that expenditure, it is probable that a transfer of economic benefits will be required in selllement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related lo the category. Resources are expended in the furtheran￿ of the charity's objectives. Grants payable are charged In the year when the offer is made exTrpt in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year-end dale are noted as a commitment bul not accrued as expenditure. Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office costs, governance costs, administrative payroll costs. They are incurred directly in support of expenditure on the objects of the charity and include project management carried out at HeadqLJarters. Vthere support costs cannot be directly atlribuled to particular headings they have been allocated to cost of raising funds and expenditure on charitable activities on a basis consistent with use of the resources. Fund-raising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable aclivilies. Tangible fixed assets Tangible fixed assets are stated at cost lor deemed costl or valuation less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable lo making the asset capable of operating as intended. All assets costing more than £200 are capilalised. Depreciation is provided at the following annual rates in order lo write off each asset over ils estimated useful Leasehold property Fixtures and fittings Computer equipment - Over 20 years Over 4 year$ Over 4 years Stocks Stocks are valued al the lower of cost and nel realISab￿ value, after making due allowance for obsolete and slow moving items. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Debtors and creditors receivable I payable within one year Debtors and creditors with no ststed interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure. Cash at bank in hand Cash at bank in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. Cash deposits that are not readily accessible within 3 months are classified as Term deposits. Provisions Provisions are recognised when the charity has an obligation al the balance sheet date as a result of a past event, it is probable that an oufflow of economic benefits will be required in selllemenl and the amount can be reliably estimated. 18

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 1 ACCOUNTING POLICIES (continued} Taxation The charity is an exempt charity within the meaning of schedule 3 of the Charities Act 2011 and is considered lo pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Fund accounting Unreslricled funds can be used in accordance with the charitable objectives at the discretion of the trustees. Restricted funds can only be used for particular reslricled purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular reslricled purposes. Further explanation of the nature and purpose of each fund is included in the notes lo the financial statements. Operating leases Rentals under operating leases are charged to the Statement of financial activities incorporating income and expenditure account on a straight line basis over the lease term. Employee benefits When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounled amount expected lo be paid in exchange for that service. The charity operates a defined contribution plan for the benefit of ils employees. Contributions are expensed as they become payable. Flnanclal Instruments The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised al transaction value and subsequently measured at their selllemenl value with the exception of bank loans which are subsequently measured al amortised cost using the effective interest method. Going concern The financial slalements have been prepared on a going concern basis as the Iruslees believe that no material uncertainties exist. The Iruslees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial slalements. The budgeted income and expenditure is sufficient with the level of reserves for the charity lo be able lo continue as a going concern. 19

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 DONATIONS AND LEGACIES 2025 2024 Donations Legacies 294.851 296.533 268,845 628,031 591,384 896,876 INCOME FROM CHARITABLE ACTIVITIES 2025 2024 Activity Infomalion and Support Subscriptions 89,437 89,742 4 OTHER TRADING ACTIVITIES 2025 2024 Fundraising events Other income Trading income 33.867 20,586 597 11,534 17.078 51,785 32,717 5 INVESTMENT INCOME 2025 2024 Investment income 161,983 98,969 20

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 EXPENDITURE 2025 2024 DIRECT COSTS OF CHARITABLE ACTIVITIES Staff costs Grants payable (see note 81 Contractors Printing magazines Subscriptions Magazine contractors Medical literature 323.032 306.370 94.281 63.631 7.286 30.904 2.800 30,900 189,654 164,828 46,261 56,068 12,035 29,999 411 54,671 Campaigns TOTAL DIRECT COSTS 859,204 553,927 Support costs {see note 71 254.518 223,413 TOTAL CHARITABLE COSTS 1113722 777,340 FUNDRAISING COSTS Direct Support costs {see note 71 95.106 26.814 64,336 23,568 121.920 87,904 TOTAL EXPENDITURE 1235 642 865,244 21

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 7 SUPPORT COSTS Basis for allocation 2025 Charitable Fundraising Governance Total staff costs Postage, telephone and slalionery Office expenses IT costs Irrecoverable VAT Depreciation Interest payable Professional fees Other costs Time spent 109,894 12,210 6.427 128.531 Pro rata usage Pro rata usage Pro rata usage Pro rats usage Pro rats usage Pro rata usage Pro rata usage Pro rata usage 21.677 6,746 24,797 20,364 11,423 6,336 17,814 22,290 2,408 749 2,755 2,263 1.269 704 1,979 2,477 24.085 7.495 27,552 22,627 12,692 6,750 26,543 24,767 241341 281332 Governance costs 254,518 26.814 281.332 Basis for allocation Charitable Fundraising Govornanco Total 2024 Staff costs Postage, telephone and stationery Office expenses IT costs Irrecoverable VAT Depreciation Interest payable Professional fees Other costs Time spent 114,411 12,712 6,691 133,814 Pro rats usage Pro rats usage Pro mta usage Pro ￿ta usage Pro rata usage Pro rata usage Pro rata usage Pro rata usage 17,904 7,014 19,796 20,228 10,728 7,287 2,206 12,548 1,989 779 2,200 2,247 1,192 810 245 1,394 19,893 7,793 21,996 22,475 11,920 8,097 7,051 13,942 4,600 212,122 11,291 223,413 23,568 11,291 11,291 246,981 Governance costs 23,568 246,981 22

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 8 GRANTS PAYABLE 2025 2024 General Fund DePaul'. Developing Consensus Research Definition.. Jason ELAROS.. MEA Clinical Assessment Toolkit App.. Phase11.' O'Brien Exeler.. MEA Count ME In Survey Analysis.. Dawes Liverpool.. Auricular Vagus Nerve Stimulation.. PhD'. Leslie Manchester.. MEA Clinical Assessment Toolkil.. Phase11.' Tyson Manchester.. Physician-caused Distress and Trauma.. Geraghty Other 5.589 7.000 16,596 2,982 2.503 9.958 3.500 440 Ramsa Fund British Columbia.. Low Dose Naltrexone Clinical Trial.. Nacul Leeds.. Testing a Personalised Dysautonomia Protocol. Sivan LSHTM". UK MEICFS Biobank Operational Costs". Nacul Manchester. MEA Clinical Assessment Toolkit. Phase l." Tyson Newcastle." FaMEly Pregnancy Study." Stage l." Pearce Surrey". Electrophysiology of MEICFS". Phase l.. Labeed Other 98,939 49,908 88,636 21,756 7,470 11,111 91,760 21,757 14,940 16,103 250 306 370 164,828 9 AUDITOR'S REMUNERATION 2025 2024 Fees payable to the charity's auditor for the audit of the charity's annual accounts 6.750 4,600 10 NET INCOMEIIEXPENDITUREI Net incomellexpendilurel is slated after chargingllcrediting}'. 2025 2024 Audilorfs remuneration Depreciation - owned assets Equipment hire 6.750 12.692 2.345 4,600 11,920 630 23

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDEO 31 DECEMBER 2025 11 TRUSTEES, REMUNERATION ANO BENEFITS There was no trustees. remuneration or other benefits for the year ended 31 De￿mber 2025 nor for the year ended 31 December 2024. Trustees. expenses During current year six Trustees received reimbursement of expenses amounting to £6,470 12024.. four Trustees re￿iVed £6,568). 12 STAFF COSTS 2025 2024 Wages and salaries Social security costs Other pension costs 463,618 39,706 16,039 344,284 21,704 9,815 519,363 375,803 The average number of employees during the year was as follows.. 2025 21 2024 15 Average employees The Key Management Personnel of the charity are represented by the trustees, who are not remunerated. 13 TANGIBLE FIXED ASSETS Leasehold Fixtures property and fittings Computer equipment Totals COST At 1 January 2025 Additions At 31 December 2025 177,712 2,482 18,405 198,599 177 712 200.550 DEPRECIATION Al 1 January 2025 Charge for the year At 31 December 2025 79,971 8,886 2,400 82 9,637 3,724 92,008 12,692 104700 NET BOOK VALUE At 31 December 2025 At 31 December 2024 97,741 82 8,768 106,591 24

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDEO 31 DECEMBER 2025 14 STOCKS 2025 2024 stocks 9.466 7,881 15 DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR 2025 2024 Other debtors Tax recoveoble Legacies Prepayments and accrued income 7,176 3,249 59,221 61,150 4,397 2,945 361,477 10,678 130,796 379,497 16 CURRENT ASSET INVESTMENTS 2025 2024 Term deposits 2.072.213 2,278,750 17 CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR 2025 2024 Trade creditors Social security and other taxes Other creditors Grant commitments Accruals and deferred income 12.006 10.862 28.145 49.908 40.597 10,867 7,457 33,118 21,757 45,588 141.518 118,787 Oeferred income Deferred income represents deferred annual membership subscriptions. 2025 2024 Deferred income al 1 January Resources deferred during the year Amounts released from previous years Deferred income al 31 De￿mber 40.723 40,597 140.7231 40.597 37,860 40,723 137,8601 40,723 25

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDEO 31 DECEMBER 2025 18 MOVEMENT IN FUNDS Net Transfers movement between in funds funds At 1.1.25 At 31.12.25 Unrestricted funds General Fund - Unreslricled Designated Fund - Sinking Fund Designated Fund - Core Services Designated Fund - Research Project Designated Fund - Healthcare Research Designated Fund - Fixed Assets 1.326,948 10,000 550,000 1,200,000 1182.258) 414,150 5,000 1550,0001 1200,0001 235,000 95,850 1.558.840 15.000 1.000.000 235.000 95.850 2,904,690 3,086,948 1182,2581 Restricted funds Ramsay Research Fund 774,922 1158,7951 616,127 TOTAL FUNDS 3 861870 341053 3.520.817 Nel movement in funds, included in the above are as follows.. Movement in funds Income Expenditure Unrestricted funds General Fund - Unreslricled 775.5PA 1957,8221 (182.2581 Restricted funds Ramsay Research Fund 119,025 1277,8201 1158,7951 TOTAL FUNDS 894,589 1,235,642 341053 26

THE MYALGIC ENCEPHALOPATHY ASSOCIATION LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDEO 31 DECEMBER 2025 18 MOVEMENT IN FUNDS Icontinuedl Comparatives for movement in funds Net movement in funds Transfers between funds At 1.1.24 At 31.12.24 Unrestricted funds General Fund - Unreslricled Designated Fund - Sinking Fund Designated Fund - Core Services Designated Fund - Research Project 2,335,428 5,000 490,500 256,020 11,264,500) 5,000 59,500 1,200,000 1,326,948 10,000 550,000 1,200,000 3,086,948 2,830,928 256,020 Restricted funds Ramsay Research Fund 777,882 (2,9601 774,922 TOTAL FUNDS 3,608,810 253,060 3,861,870 Nel movement in funds, included in the above are as follows.. Movement in funds Income Expenditure Unrestricted funds General Fund - Unreslricled 976,454 1720,4341 256,020 Rostricted funds Ramsay Research Fund 141,850 1144,8101 12,9601 TOTAL FUNDS 1,118,304 1865,2441 253,060 27